Original articleLipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Société Francophone d’Athérosclérose (NSFA)Lipoprotéine (a) : physiopathologie, indication de dosage et traitement dans les MCV. Déclaration de consensus de la Nouvelle Société Francophone d’Athérosclérose (NSFA)☆
Graphical abstract
Central Illustration. Pathophysiological pathways providing a causal link between high plasma concentrations of lipoprotein(a) (Lp(a)) and atherosclerotic vascular disease and aortic valve stenosis (AVS). Clinical outcomes are related to accelerated atherosclerosis complicated by atherothrombosis (myocardial infarction, stroke), peripheral artery disease (PAD) or aortic valve replacement (AVR) caused by valve calcification and aortic stenosis. Apo(a): apolipoprotein(a); LDL: low-density lipoprotein; OxPL: oxidized phospholipids; NSFA: Nouvelle Société Francophone d’Athérosclérose; SP: serine-protease domain; V: plasminogen kringle V (reproduced with permission).
Keywords
Mots clés
Abbreviations
Cited by (0)
- ☆
Tweet: In this consensus statement we present evidence for a causal role of Lp(a) in the pathophysiology of atherothrombosis from prospective epidemiological and genetic studies, as well as the partial homology of apo(a) with plasminogen, which underlies its ability to attenuate fibrinolysis and promote the development of thrombosis.
- 1
Twitter address: @AnglescanoE.